In a 39-year-old male taking Auvelity (dextromethorphan‑bupropion) and Concerta (methylphenidate) who regularly consumes coffee and energy drinks, what are the likely causes and recommended management for daily tongue‑to‑tooth picking, constant excessive eye blinking, and persistent leg shaking that worsen with caffeine intake or anxiety?

Medication-Induced Movement Disorders and Oral Stereotypies

These symptoms—tongue-to-tooth picking, excessive eye blinking, and leg shaking—are most likely medication-induced movement disorders from the combination of Auvelity (dextromethorphan-bupropion) and Concerta (methylphenidate), significantly exacerbated by excessive caffeine intake from coffee and energy drinks.

Primary Cause: Stimulant-Induced Movement Disorders

The patient is experiencing a constellation of extrapyramidal-like symptoms and stereotypic movements that are well-documented adverse effects of psychostimulants. The FDA label for Auvelity explicitly lists extrapyramidal syndrome (dyskinesia, dystonia) and restlessness as postmarketing adverse reactions associated with bupropion 1. Methylphenidate guidelines confirm that motor tics and stereotypic movements can occur with stimulant treatment, though controlled studies show variable individual responses 2.

Specific Symptom Analysis:

Tongue-to-Tooth Picking (Oral Stereotypy):

• This represents a drug-induced oral stereotypy or bruxism-like behavior
• Psychostimulants commonly cause oral adverse effects including bruxism and repetitive oral movements 3
• The bupropion component of Auvelity is specifically associated with agitation, restlessness, and repetitive behaviors 1
• This behavior worsening with caffeine suggests additive dopaminergic/noradrenergic overstimulation

Excessive Eye Blinking:

• This is a motor tic or blepharospasm induced by stimulant medications
• While guidelines note that methylphenidate doesn't typically worsen tics in most patients 2, individual responses vary significantly
• The patient correctly identifies worsening with energy drinks, indicating dose-dependent stimulant effect
• Bupropion postmarketing data includes extrapyramidal symptoms and dyskinesia 1

Leg Shaking (Akathisia/Restlessness):

• This represents psychomotor agitation or akathisia, a classic stimulant adverse effect
• The FDA label for Auvelity lists agitation (4% incidence), restlessness, and anxiety as common adverse reactions 1
• Stimulant guidelines confirm that "motor activity and agitation/excitement" are typical of central stimulant activity 4
• The anxiety-triggered and focus-related pattern suggests underlying stimulant-induced hyperarousal

Critical Caffeine Contribution

The patient's consumption of multiple cups of coffee plus energy drinks is creating dangerous polypharmacy with stimulant medications. Caffeine is a methylxanthine stimulant that:

• Potentiates dopaminergic and noradrenergic effects of methylphenidate and bupropion
• Lowers seizure threshold (critical concern with bupropion, which already carries seizure risk) 1
• Exacerbates movement disorders, tremor, and akathisia 4
• The patient's own observation that symptoms worsen with caffeine confirms this mechanism

Immediate Management Algorithm

Step 1: Eliminate Caffeine Immediately

• Discontinue all coffee and energy drinks completely
• This is non-negotiable given the additive stimulant effects and seizure risk
• Taper gradually over 3-5 days if consuming >400mg daily to avoid withdrawal headaches
• Switch to decaffeinated beverages

Step 2: Medication Review and Adjustment

Evaluate total stimulant burden:

• The combination of Auvelity (which contains bupropion, a norepinephrine-dopamine reuptake inhibitor) plus Concerta (methylphenidate) creates dual dopaminergic/noradrenergic stimulation
• Consider whether both medications are necessary or if monotherapy would suffice

Specific medication adjustments (in order of priority):

1. Reduce Concerta dose first (if ADHD symptoms allow):

   • Methylphenidate has shorter half-life and more direct stimulant effects
   • Dose reduction may rapidly improve motor symptoms within 1-3 days
   • Monitor ADHD symptom control carefully

2. If movement disorders persist, consider switching from Auvelity to bupropion monotherapy:

   • The dextromethorphan component (NMDA antagonist) may contribute to neuropsychiatric effects 1
   • Bupropion alone has lower incidence of extrapyramidal symptoms
   • This maintains depression treatment while reducing movement disorder risk

3. Alternative: Switch Concerta to non-stimulant ADHD medication:

   • Consider atomoxetine or guanfacine if ADHD requires continued treatment
   • These lack the motor side effects of stimulants 2

Step 3: Monitor for Improvement

• Movement disorders should improve within 1-2 weeks of caffeine elimination and dose reduction
• If symptoms persist beyond 2 weeks, consider complete discontinuation of one agent
• Document symptom frequency and severity using patient diary

Critical Safety Concerns

Seizure Risk: The combination of bupropion (dose-dependent seizure risk) plus methylphenidate plus caffeine creates compounded seizure risk 2, 1. The FDA label warns that bupropion can cause seizures, particularly at higher doses or with concomitant stimulants 1.

Serotonin Syndrome Risk: While less likely, the combination of dextromethorphan (sigma-1 agonist with serotonergic properties) and bupropion requires monitoring for serotonin syndrome symptoms 1.

Cardiovascular Monitoring: Both medications increase blood pressure and heart rate. The FDA label for Auvelity specifically warns about hypertension 1, and stimulant guidelines note cardiovascular risks 4. Check blood pressure at each visit.

Common Pitfalls to Avoid

1. Do not add additional medications (e.g., benzodiazepines for anxiety, anticholinergics for movement disorders) before addressing the root cause—stimulant excess
2. Do not dismiss patient's caffeine observation—this is a critical diagnostic clue
3. Do not continue both medications at full dose while "monitoring"—active dose reduction is required
4. Do not assume these are primary tic disorders—they are medication-induced until proven otherwise

When to Refer

• If movement disorders persist >4 weeks after medication adjustment, refer to neurology to rule out tardive dyskinesia or other primary movement disorders
• If patient cannot function without both medications at current doses, refer to psychiatry for alternative treatment strategies
• If seizures occur, discontinue bupropion immediately and refer to neurology

The most important intervention is immediate and complete caffeine cessation combined with reduction of total stimulant burden through dose adjustment or medication simplification.